ImmuCell Corp. (ICCC)
9.96
+0.08
(+0.81%)
USD |
NASDAQ |
May 21, 16:00
9.96
0.00 (0.00%)
After-Hours: 18:45
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 90.11M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 78.34% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 3.009 |
| Price to Book Value | 3.093 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.4386 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 70.29% |
Profile
| ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. It operates through the following segments: Scours and Mastitis. The Scours segment consists of the First Defense product line. The Mastitis segment includes the CMT product line consisting of reagents and equipment used for rapid cow-side testing to identify mastitic quarters by detecting elevated somatic cell counts. The company was founded in 1982 and is headquartered in Portland, ME. |
| URL | http://www.immucell.com |
| Investor Relations URL | http://immucell.com/quick-facts-corporate-governance/ |
| HQ State/Province | Maine |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Aug. 13, 2026 (est.) |
| Last Earnings Release | May. 14, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. It operates through the following segments: Scours and Mastitis. The Scours segment consists of the First Defense product line. The Mastitis segment includes the CMT product line consisting of reagents and equipment used for rapid cow-side testing to identify mastitic quarters by detecting elevated somatic cell counts. The company was founded in 1982 and is headquartered in Portland, ME. |
| URL | http://www.immucell.com |
| Investor Relations URL | http://immucell.com/quick-facts-corporate-governance/ |
| HQ State/Province | Maine |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Aug. 13, 2026 (est.) |
| Last Earnings Release | May. 14, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |